Pharma
Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST
AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk
Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!
Read
Commented by Nico Popp on October 21st, 2025 | 07:10 CEST
Biotech investors should know these suppliers: Thermo Fisher Scientific, BioNxt, AptarGroup
While new drugs dominate the headlines, it is often suppliers and service providers that deliver solid long-term returns. Three examples: Thermo Fisher Scientific, BioNxt Solutions, and AptarGroup - all key enablers for pharmaceutical and biotech companies. We present their business models and markets, highlighting where investors can spot particular opportunities – especially BioNxt, which occupies exciting niches with its innovations.
Read
Commented by Fabian Lorenz on October 20th, 2025 | 07:15 CEST
Almost 150% upside potential! Plug Power, Bayer, Planethic Group
Is Planethic Group (formerly Veganz Group) offering the buying opportunity of the fall? Analysts see over 100% upside potential. The recent correction appears exaggerated and could be an attractive entry point. The Company itself reports massive demand. Plug Power shares have performed strongly in recent months. Instead of taking profits, analysts see further upside — although some voices remain cautious, as the Company has promised to reach break-even many times before. And what do analysts say about Bayer? Very little at the moment. Goldman Sachs recommends the stock as a "Buy", but there is potential for a setback with the upcoming Q3 figures.
Read
Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST
Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves
The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST
Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!
Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.
Read
Commented by Armin Schulz on October 16th, 2025 | 07:20 CEST
Investors take note: BioNxt Solutions builds on blockbusters from Novo Nordisk and Merck - and has another ace up its sleeve in oncology
In the biotech sector, a single technology can often determine success or failure. Canadian-German company BioNxt Solutions is taking a different approach, relying on three pillars, each targeting major markets and advancing established blockbusters from leading pharmaceutical companies. October has already brought decisive progress, from accelerated patent protection to concrete milestones in development. These concentrated positive signals show that BioNxt Solutions not only has a promising concept, but also the strategy and operational strength to turn it into value. A closer analysis is worthwhile.
Read
Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST
Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation
While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.
Read
Commented by André Will-Laudien on October 14th, 2025 | 07:20 CEST
CAUTION: Correction or even steeper rise? 100% with Planethic Group, Novo Nordisk, and Symrise
Does it always have to be "caviar"? As a luxury solution, this fish dish is deeply ingrained in the minds of many investors, but sometimes a smarter, hybrid-strategic mix may suffice. In the current market environment, the latest tariff policy from the White House feels like the flickering echo of a spy from Simmel's novel: unpredictable, tactical, and with far-reaching consequences. The threat of high tariffs on imports from numerous countries is putting supply chains on high alert and forcing companies to rethink their calculations. For investors, this means acting quickly, maintaining flexible portfolio weights, and questioning seemingly "safe" values. Those who favor local procurement channels are likely to navigate more stably. Here are a few ideas.
Read
Commented by Carsten Mainitz on October 14th, 2025 | 07:15 CEST
Momentum plays with a new wave: Almonty Industries and Rheinmetall – what is Gerresheimer doing?
The trade dispute between the US and China appears to be entering the next round. Late last week, US President Trump announced his intention to impose additional punitive tariffs of 100% on Chinese goods. The measures are expected to take effect by November at the latest. This follows China's decision to tighten export controls on certain technologies and raw materials. China holds many critical raw materials and is gradually restricting their export. While consumers face major challenges in view of the shortage of demand and rising prices, producers of these raw materials are among the stock market favorites.
Read
Commented by Stefan Feulner on October 13th, 2025 | 07:35 CEST
BioNxt Solutions – Attack on new highs
After global stock markets had been on an upward trajectory in recent weeks, US President Donald Trump caused some irritation with a post on his social media platform, "Truth Social." The escalating trade dispute with China, the world's second-largest economy, caused the already overvalued markets to falter. The DAX lost just under 1.8% at the end of the week, while the Nasdaq technology index suffered significantly more, losing just under 4.3%. In the coming weeks, stock picking is likely to take center stage. Against this backdrop, BioNxt Solutions, a life sciences company specializing in innovative technologies for next-generation drug delivery, was able to shine with fundamental milestones and buck the negative trend.
Read